Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

DARA BioSciences commences $10M underwritten public offering

DARA BioSciences, Inc. announced today that it has commenced an underwritten public offering of $10 million of units comprised of shares of common stock and warrants. The company intends to grant the underwriter in the offering an option to purchase up to $1.5 million of additional units to cover any over-allotments.

17 May 2010

Treatment with MP-376 reduces P. aeruginosa in CF patients: Research

A new possible treatment to treat P. aeruginosa in cystic fibrosis patients appears to be promising, according to research to be presented at the ATS 2010 International Conference in New Orleans.

17 May 2010

Data from RGN-259 study published in Archives of Ophthalmology

RegeneRx Biopharmaceuticals, Inc. announced today the publication of the first human data from a case study of patients evaluated with its ophthalmic product candidate RGN-259. The data have been published in the May 2010 issue of Archives of Ophthalmology, an American Medical Association peer-reviewed journal.

14 May 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.

14 May 2010

Aradigm reports total revenue of $4.0M for first-quarter 2010

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2010.

13 May 2010

Gene patenting policies affect patient access to testing for disease-causing genes: Study

Policies allowing genes to be patented can make it more difficult for patients to access testing for important disease-causing gene mutations, according to a series of papers in a special online supplement published by Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.

7 May 2010

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.

5 May 2010

Decisive impact of informatics on nanomedicine

According to what researchers from Facultad de Informática and other institutions have advanced in an article just published in the prestigious medical journal Pediatric Research (Vol.6, No. 5, 2010), nanoparticles are poised to play a key role in medical research in the coming decades, when nanomedicine will become part of medical practice.

5 May 2010

Azithromycin does not improve lung function in children with cystic fibrosis

Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared to patients who received placebo, according to a study in the May 5 issue of JAMA.

5 May 2010

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.

4 May 2010

ZENPEP CF Cycle for Life to be launched to support research and cure for cystic fibrosis

Thousands of cyclists will take to the streets this summer and fall as the Cystic Fibrosis Foundation launches a new cycling tour in 18 cities across the country to support research to find new therapies and a cure for cystic fibrosis. The tour series, known as ZENPEP CF Cycle for Life, begins in San Francisco on June 26.

4 May 2010

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.

3 May 2010

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2010, reporting a net loss of $14.8 million or ($0.18) per share.

3 May 2010

Measuring children's blood pressure is complicated: Researchers

A Johns Hopkins Children's Center study of 2,500 patient records suggests that medical staff fails to check a child's blood pressure a fifth of the time, and is not recognizing what constitutes an abnormal reading in those whose blood pressure they do check.

3 May 2010

Stanford University's Herzenberg Lab wins 2010 Laureate in Computerworld Honors Program

Stanford University's Herzenberg Laboratory is a 2010 Laureate in the prestigious Computerworld Honors Program. SAS, the leader in business analytics software and services, announced the award today.

30 Apr 2010

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.

28 Apr 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Pharmacological suppression of nonsense mutations effective in treating genetic defects

Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.

27 Apr 2010

Scientists now closer to produce drugs to fix disease-causing mutations, spare healthy genes

Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.

27 Apr 2010

NHS funding a major issue in the coming election

The state of the British economy has made the cut backs in NHS funding a major issue in the coming election. However no matter what the posturing is right now, and no politician wants to be seen making cuts here, there may be no other viable alternatives. No matter who forms the government after 6th May, they will be under great strain to keep their earlier promises of no health fund cuts.

27 Apr 2010

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

DARA BioSciences commences $10M underwritten public offering

Treatment with MP-376 reduces P. aeruginosa in CF patients: Research

Data from RGN-259 study published in Archives of Ophthalmology

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

Aradigm reports total revenue of $4.0M for first-quarter 2010

Gene patenting policies affect patient access to testing for disease-causing genes: Study

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Decisive impact of informatics on nanomedicine

Azithromycin does not improve lung function in children with cystic fibrosis

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

ZENPEP CF Cycle for Life to be launched to support research and cure for cystic fibrosis

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Measuring children's blood pressure is complicated: Researchers

Stanford University's Herzenberg Lab wins 2010 Laureate in Computerworld Honors Program

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Pharmacological suppression of nonsense mutations effective in treating genetic defects

Scientists now closer to produce drugs to fix disease-causing mutations, spare healthy genes

NHS funding a major issue in the coming election

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in